CTOs on the Move

Solid Biosciences

www.solidbio.com

 
Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients. Solid is headquartered in Cambridge, MA, USA.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.solidbio.com
  • 141 Portland Street Fifth Floor
    Cambridge, MA USA 02139
  • Phone: 617.337.4680

Executives

Name Title Contact Details
Keith Clark
 Senior Director Information Technology Profile
Keith Clark
 Associate Director, Information Technology Profile

Funding

Solid Biosciences raised $42.5M on 11/03/2015
Solid Biosciences raised $50M on 03/30/2017
Solid Biosciences raised $40M on 10/23/2020
Solid Biosciences raised $90M on 12/11/2020
Solid Biosciences raised $143.8M on 03/21/2021

Similar Companies

Mabtech Inc

Mabtech Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SkinMedica

SkinMedica, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cadent Therapeutics

Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.

Puget Sound Kidney Centers

Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.